[{“box”:0,”content”:”[if 992 equals=”Open Access”]n
n
Open Access
nn
n
n[/if 992]n
n
n
n
n
n
Himanshu Solanki, Neha Patil, Jaydatta Dhakane, Shruti Adhikari
n
- n t
n
n
n[/foreach]
n
n[if 2099 not_equal=”Yes”]n
- [foreach 286] [if 1175 not_equal=””]n t
- Associate Professor, PG Scholar, PG Scholar, PG Scholar Department of Pharmaceutics, S.S.R. College of Pharmacy, Department of Pharmaceutics, S.S.R. College of Pharmacy, S.S.R. Campus, Sayli Road, Department of Pharmaceutics, S.S.R. College of Pharmacy, S.S.R. Campus, Sayli Road, Department of Pharmaceutics, S.S.R. College of Pharmacy, S.S.R. Campus, Sayli Road Daman & Diu, Daman & Diu, Daman & Diu, Daman & Diu India, India, India, India
n[/if 1175][/foreach]
n[/if 2099][if 2099 equals=”Yes”][/if 2099]n
Abstract
nCapecitabine, a precursor to 5-fluorouracil (5-FU), is Anticancer Drug in treating solid tumors like colorectal, breast, and gastric cancers. Its mechanism involves converting to 5-FU mainly within tumor cells, reducing toxicity while maximizing effectiveness. Besides being effective alone, it is also valuable in combination therapies, showcasing its versatility in cancer treatment. This review explores the transformative journey of capecitabine as a pivotal anticancer drug. Beginning with an introduction to its mechanism of action, drug profile, pharmacokinetics, and pharmacodynamics, the review provides a comprehensive overview of capecitabine’s pharmacological characteristics. It further examines the application of capecitabine in various cancers, including colorectal, breast, gastric, and others, highlighting its efficacy and clinical benefits. Moreover, the review delves into capecitabine’s integration into combination regimens, such as with oxaliplatin or docetaxel, emphasizing its role in enhancing treatment outcomes and expanding therapeutic options. Through elucidating capecitabine’s evolution and versatility, this review underscores its significance as a cornerstone in modern cancer therapy. The continued exploration of it’s therapeutic potential promises to unlock new avenues for improving cancer treatment and patient outcomes, reaffirming its status as an essential component in the fight against cancer.
n
Keywords: Capecitabine, 5-fluorouracil, Anticancer Drug, Pharmacokinetics, Antineoplastic Drugs.
n[if 424 equals=”Regular Issue”][This article belongs to Research & Reviews: A Journal of Drug Design & Discovery(rrjoddd)]
n
n
n
n
n
nn[if 992 equals=”Open Access”] Full Text PDF Download[/if 992] n[if 992 not_equal=”Open Access”]
[/if 992]n[if 992 not_equal=”Open Access”] nn
n[/if 992]nn[if 379 not_equal=””]nBrowse Figures
n
n[/if 379]n
References
n[if 1104 equals=””]n
1) Vanave A, Chougle N, Kamble J, Salokhe P. Capecitabine: A Promising Anticancer Drug. JOPIR. 2024;2(1):102-107p.
2) Heidelberger C, Chaudhuri N, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179(4561):663-666p.
3) Walko C, Lindley C. Capecitabine: a review. Clin. Ther. 2005;27(1):23-44p.
4) Johnston P, Kaye S. Capecitabine: a novel agent for the treatment of solid tumors. Anti-cancer drugs. 2001;12(8):639-646p.
5) Petrelli F, Cabiddu M, Barni S. 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials. Medical Oncology. 2012;29:1020-1029p.
6) Iacovelli R, Pietrantonio F, Palazzo A, Maggi C, Ricchini F, de Braud F, Di Bartolomeo M. Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5‐fluorouracil: a meta‐analysis of published trials. Br. J. Clin. Pharmacol. 2014;78(6):1228-1237p.
7) Polk A, Vaage-Nilsen M, Vistisen K, Nielsen D. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat. Rev. 2013;39(8):974-984p.
8) Chakraborty S. Medicinal plants and cervical cancer therapy: An overview. JPP. 2019;8(3):3633-3641p.
9) Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer. 1998;34(8):1274-1281p.
10) Budman D, Meropol N, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. Clin. Oncol. 1998;16(5):1795-1802p.
11) Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291-297p.
12) Cutsem V. Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-4106p.
13) Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol. 1998;16(9):2977-2985p.
14) Judson IR, Beale PJ, Trigo JM, et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs. 1999;17:49-56p.
15) Sternberg C, Reichardt P, Holland M. Development of and clinical experience with capecitabine (Xeloda®) in the treatment of solid tumours. EJON. 2004;8:S4-15p.
16) Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin. Pharmacokinet. 2001;40:85-104p.
17) Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 1998;4(4):941-948p.
18) Nutley NJ. Xeloda (capecitabine)[product information]. Roche Pharmaceuticals. 2003.
19) Twelves C, Budman D, Creaven P, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies. In Proc Am Soc Clin Oncol. 1996;(15):476-489p.
20) Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin. Cancer Res. 1999;5(7):1696-1702p.
21) McKendrick J, Coutsouvelis J. Capecitabine: effective oral fluoropyrimidine chemotherapy. Expert Opin Pharmacother. 2005;6(7):1231-1239p.
22) Longley D, Harkin D, Johnston P. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer. 2003;3(5):330-338p.
23) Miura K, Kinouchi M, Ishida K, et al. 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers. 2010;2(3):1717-1730p.
24) Shimma N, Umeda I, Arasaki M, et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. BMCL. 2000;8(7):1697-1706p.
25) Blum J, Jones S, Buzdar A, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 1999;17(2):485-392p.
26) Hortobagyi G. Treatment of breast cancer. NEJM. 1998;339(14):974-984p.
27) Cohen A. Cancer of the colon. Cancer Principles & Practice of Oncology. 1997:1144-1197p.
28) Hoff P, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J. Clin. Oncol. 2001;19(8):2282-2292p.
29) Hirsch B, Zafar S. Capecitabine in the management of colorectal cancer. Cancer management and research. 2011:79-89p.
30) Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs. 2000;18:343-354p.
31) Morant R, Bernhard J, Dietrich D, et al. Capecitabine in hormone-resistant metastatic prostatic carcinoma–a phase II trial. Br. J. Cancer. 2004;90(7):1312-1317p.
32) Vasey P, McMahon L, Paul J, Reed N, Kaye S. A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer. Br. J. Cancer. 2003;89(10):1843-1848p.
33) Twelves C. Vision of the future: capecitabine. J. Oncol. 2001;6(S4):35-39p.
34) Wenzel C, Schmidinger M, Locker G, et al. Oral chemotherapy with capecitabine (Xeloda) in the treatment of metastatic renal cancer failing immunotherapy. In Proc Am Soc Clin Oncol. 2000;19:368-377p.
35) Vaishampayan U, Heilbrun L, Eliason J, Pontes E, Forman J, Cher M. Phase II trial of weekly docetaxel and capecitabine in advanced renal cell carcinoma. J. Clin. Oncol. 2004;22(14):4672-4679p.
36) Boeck S, Hoehler T, Seipelt G, et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann. Oncol. 2008;19(2):340-347p.
37) Park Y, Ryoo B, Choi S, Kim H. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br. J. Cancer. 2004;90(7):1329-1333p.
38) Ryu M, Yoo C, Kim J, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur. J. Cancer. 2015;51(4):482-488p.
39) Hsu C, Yang T, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer. 2010;102(6):981-986p.
40) Weiss J, Bagley S, Hwang W,et al. Capecitabine and lapatinib for the first‐line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer. 2016;122(15):2350-2355p.
nn[/if 1104][if 1104 not_equal=””]n
- [foreach 1102]n t
- [if 1106 equals=””], [/if 1106][if 1106 not_equal=””],[/if 1106]
n[/foreach]
n[/if 1104]
nn
nn[if 1114 equals=”Yes”]n
n[/if 1114]
n
n
n
Research & Reviews: A Journal of Drug Design & Discovery
n
n
n
n
n
n
| Volume | ||
| [if 424 equals=”Regular Issue”]Issue[/if 424][if 424 equals=”Special Issue”]Special Issue[/if 424] [if 424 equals=”Conference”][/if 424] | ||
| Received | May 27, 2024 | |
| Accepted | June 4, 2024 | |
| Published | June 21, 2024 |
n
n
n
n
n
n function myFunction2() {n var x = document.getElementById(“browsefigure”);n if (x.style.display === “block”) {n x.style.display = “none”;n }n else { x.style.display = “Block”; }n }n document.querySelector(“.prevBtn”).addEventListener(“click”, () => {n changeSlides(-1);n });n document.querySelector(“.nextBtn”).addEventListener(“click”, () => {n changeSlides(1);n });n var slideIndex = 1;n showSlides(slideIndex);n function changeSlides(n) {n showSlides((slideIndex += n));n }n function currentSlide(n) {n showSlides((slideIndex = n));n }n function showSlides(n) {n var i;n var slides = document.getElementsByClassName(“Slide”);n var dots = document.getElementsByClassName(“Navdot”);n if (n > slides.length) { slideIndex = 1; }n if (n (item.style.display = “none”));n Array.from(dots).forEach(n item => (item.className = item.className.replace(” selected”, “”))n );n slides[slideIndex – 1].style.display = “block”;n dots[slideIndex – 1].className += ” selected”;n }n”}]